Balanced news tone
News Sentiment
001630 sentiment intelligence
Chong Kun Dang Holdings Corp. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
84/100 classification confidence.
directly relevant articles
high-authority source matches
-2.0% over one week, -5.2% over four weeks, trend inactive, and below fair value.
Price to sales forward of Chong Kun Dang Holdings Co., Ltd. – KRX:001630
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Price to sales forward of Chong Kun Dang Holdings Co., Ltd. – KRX:001630
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jul 2026 08:37
- Source
- TradingView
Chong Kun Dang Launches Archela for Drug Development
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Mar 2026 07:00
- Source
- 조선일보
Chong Kun Dang invests ₩12.2 bil in AbClon, gains CAR-T commercialization rights
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 12 May 2025 07:00
- Source
- koreabiomed.com
Chong Kun Dang launches dual-format product to capture bigger share of South Korea’s thriving hangover cure market
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Oct 2024 07:00
- Source
- NutraIngredients.com
Brand new: Chong Kun Dang Healthcare rides on GLP-1 boom and new launches from Fast&Up, Kalbe
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2024 07:00
- Source
- NutraIngredients.com
Chong Kun Dang scores its ‘largest ever’ $1.3B deal with Novartis for CKD-510
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 07 Nov 2023 08:00
- Source
- BioWorld News
Chong Kun Dang rallies on $1.3 bn deal with Novartis
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 06 Nov 2023 08:00
- Source
- KED Global
Novartis Bags Chong Kun Dang’s HDAC6 Inhibitor In $1.3bn Deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 06 Nov 2023 08:00
- Source
- insights.citeline.com
Chong Kun Dang licenses out HDAC6 inhibitor CKD-510 to Novartis for $1.3 billion
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Nov 2023 08:00
- Source
- koreabiomed.com
[Combination Drug Rave ⑦] Chong Kun Dang aims to enter glaucoma market by solving hygroscopicity in Telminuvo
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Dec 2020 08:00
- Source
- koreabiomed.com